Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 22Salivary Gland Neoplasms 3Prostate Adenocarcinoma 2Neoplasm Metastasis 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Primary Dysautonomias 1Patient Compliance 1PSA Level Greater Than Two 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Castrate Sensitive Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

enzalutamide 3darolutamide 2abiraterone 2pembrolizumab 1bicalutamide 1abemaciclib 1Prednisolone 1Goserelin 1Docetaxel 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × Goserelin × 1 year × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡